Intravitreal vascular endothelial growth factor inhibitors did not increase the risk of end-stage renal disease in patients with biopsy-proven diabetic kidney disease based on matched study

• Main Authors: Xiang Xiao (Author), Junlin Zhang (Author), Shuming Ji (Author), Yutong Zou (Author), Yucheng Wu (Author), Chunmei Qin (Author), Jia Yang (Author), Yuancheng Zhao (Author), Qin Yang (Author), Fang Liu (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Purpose: This study aimed to investigate the effects of intravitreal (IVT) VEGFi on long-term renal outcomes in patients with biopsy-proven diabetic kidney disease (DKD).Patients and methods: Patients prescribed IVT VEGFi (VEGFi group) were enrolled from a retrospective cohort with biopsy-proven DKD...